Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Public ClinicalTrials.gov record NCT03338296. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Study identification
- NCT ID
- NCT03338296
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 278 participants
Conditions and interventions
Conditions
Interventions
- lorcaserin hydrochloride XR Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2017
- Primary completion
- Apr 2, 2020
- Completion
- Apr 2, 2020
- Last update posted
- Jul 18, 2021
2017 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Clinical LLC | Phoenix | Arizona | 85014 | — |
| Alliance Research Institute | Bell Gardens | California | 90201 | — |
| Long Beach Clinical Trial Services, Inc | Long Beach | California | 90806 | — |
| International Research Partners LLC | Doral | Florida | 33122 | — |
| Oviedo Medical Research, LLC | Oviedo | Florida | 32765 | — |
| Gwinnett Research Institute | Buford | Georgia | 30519 | — |
| Columbus Regional Research Institute | Columbus | Georgia | 31904 | — |
| Buynak Clinical Research, PC | Valparaiso | Indiana | 46383 | — |
| Heartland Research Associates, LLC | Wichita | Kansas | 67207 | — |
| The Center for Pharmaceutical Research, LLC | Kansas City | Missouri | 64114 | — |
| Wake Research-Clinical Research Center of Nevada, LLC | Henderson | Nevada | 89014 | — |
| Diabetes & Endocrinology Consultants, PC | Morehead City | North Carolina | 28557 | — |
| Neuro-Behavioral Clinical Research, Inc | North Canton | Ohio | 44720 | — |
| Celia Reyes-Acuna, MD | Corpus Christi | Texas | 78413 | — |
| DCT-McAllen Primary Care, LLC dba Discovery Clinical Trials | McAllen | Texas | 78503 | — |
| National Clinical Research-Richmond, Inc | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03338296, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03338296 live on ClinicalTrials.gov.